Keppra
Partial Onset Seizures
UCB Japan Co. Ltd.Phase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Partial Onset Seizures cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lacosamide UCB Pharma SA | Phase 3 | BB |
Pregabalin Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 3 | B |
SELURAMPANEL Novartis Pharmaceuticals | Phase 2 | B |
Fycompa Eisai Limited | D |
Same molecule, other indications
Keppra is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →